Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Evogene Ltd. Foreign Filer Report 2021

Jul 6, 2021

6785_ffr_2021-07-06_aaadab8c-9072-455f-a913-9ee15405d2a8.zip

Foreign Filer Report

Open in viewer

Opens in your device viewer

6-K 1 zk2126266.htm 6-K Licensed to: Z-K Global Document created using EDGARfilings PROfile 7.5.0.0 Copyright 1995 - 2021 Broadridge

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2021

Commission File Number: 001-36187

EVOGENE LTD.

(Translation of Registrant’s Name into English)

13 Gad Feinstein Street

Park Rehovot P.O.B 4173

Ness Ziona 7414003, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

CONTENTS

On July 6, 2021, Evogene Ltd. (“ Evogene ”) announced positive results for a herbicide resistance trait to a leading herbicide product candidate of its subsidiary Ag Plenus Ltd. (“ AgPlenus ”). A copy of the press release is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K (this “ Form 6-K ”) and is incorporated herein by reference.

The contents of Exhibit 99.1 to this Form 6-K, excluding the statements of AgPlenus’ CEO and Evogene’s President and CEO, contained therein, are incorporated by reference in the registration statements on Form F-3 (Securities and Exchange Commission (“ SEC ”) File No. 333-253300), and Form S-8 (SEC File Nos. 333-193788, 333-201443 and 333-203856) of Evogene, and will be a part thereof from the date on which this Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: July 6, 2021 EVOGENE LTD. (Registrant) By: /s/ Dorit Kreiner Dorit Kreiner Chief Financial Officer

EXHIBIT INDEX

EXHIBIT NO. DESCRIPTION
99.1 Press Release: AgPlenus
Announces Positive Results for a Herbicide Resistance Trait to its Leading Herbicide Product Candidate.